1.   Millennium said it will bear the costs of developing the drug, now in the first phase of human testing, as well as manufacturing and marketing it.

2.   Millennium said last year it identified two disease genes that have been shown to cause obesity in animals.

3.   Millennium said it will pay an undisclosed upfront fee for the five-year deal and royalties on net sales of any products developed from the licensed antibodies.

4.   Millennium said the proposed anti-inflammatory medication is being developed with Genentech Inc. of South San Francisco, which also holds worldwide commercialization rights.